A doxycycline- and light-inducible Cre recombinase mouse model for optogenetic genome editing.
Vizoso M, E J Pritchard C, Bombardelli L, van den Broek B, Krimpenfort P, Beijersbergen RL, Jalink K, van Rheenen J
Nat Commun. 2022 Oct 28;13(1):6442. doi: 10.1038/s41467-022-33863-z. PubMed Article
Vizoso M, E J Pritchard C, Bombardelli L, van den Broek B, Krimpenfort P, Beijersbergen RL, Jalink K, van Rheenen J
Nat Commun. 2022 Oct 28;13(1):6442. doi: 10.1038/s41467-022-33863-z. PubMed Article
Plasmids from Article
| ID | Plasmid | Purpose |
|---|---|---|
| 198752 | DiLiCre 2.0 | A Cre recombinase that is expressed upon doxycycline when combined with the UbC-blasticidine-P2A-TETon-3G transactivator. DiLiCre 2.0 is a cre recombinase that is activated by violet light. |
| 198753 | EF1α-Lox2272-LoxP-MARKS·mTurquoise2-NLS·turboRFP-Lox2272-LoxP | Cre reporter, which switches from membraneous mTurquoise to nuclear RFP upon Cre recombinase activity |
| 200191 | UbC-blasticidine-P2A-TETon-3G transactivator | A TETon activator, which combined with the DiLiCre 2.0 plasmid, drives the expression of DiLiCre 2.0 upon doxycycline. DiLiCre 2.0 is a cre recombinase that is activated by violet light. |